M1409 HCPCS Level II code: Patients who received germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis
M1409 is the HCPCS code for “Patients who received germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
M1409Patients who received germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis
Short description: Recd gmln brca1/brca2 couns
HCPCS · United States
Medicare details
The indicators CMS publishes with M1409 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)
- Type of service
- Medical care
- BETOS category
- Undefined codes
- Added
- Jan 1, 2025
Where M1409 sits
- 1M codesMedical services and quality measures
- 2Active code M1409Patients who received germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code M1409 mean?
M1409 is the HCPCS code for “Patients who received germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover M1409?
CMS lists M1409’s Medicare coverage as “Carrier judgment” and its pricing as “Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside M1409
All M codesM1403Patients with baseline and follow-up promis surveys documented in the medical recordM1404Patients on a therapeutic clinical trialM1405Patients with recurrence/disease progressionM1406Patients who leave the practice during the follow-up periodM1407Patients who died during the follow-up periodM1408Patients who have germline brca testing completed before diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancerM1410Patients who did not have germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosisM1411Currently on first-line immune checkpoint inhibitors without chemotherapyM1412Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved…M1413Patients who had a positive pd-l1 biomarker expression test result prior to the initiation of first-line immune checkpoint inhibitor therapyM1414Documentation of medical reason(s) for not performing the pd-l1 biomarker expression test prior to initiation of first-line immune checkpoint inhibitor therapy (e.g., patient is…M1415Patients who did not have a positive pd-l1 biomarker expression test result prior to the initiation of first-line immune checkpoint inhibitor therapy